Medpace Holdings CEO August J. Troendle Sells $15.36M in Common Stock

Insider Transaction Analysis: Medpace Holdings, Inc. (NASDAQ: MEDP)

Overview

On September 17, 2026, August J. Troendle, President, Chief Executive Officer, Director, and 10% Owner of Medpace Holdings, Inc., reported open-market sales of common stock totaling 24,741 shares across two consecutive trading days (September 15 and September 16, 2026). Total proceeds amounted to approximately $15.36 million.

Transaction Details

• September 15, 2026: Sold 15,971 shares at a weighted average price of $620.84 (ranging from $620.00 to $622.84), realizing $9,915,435.64.
• September 16, 2026: Sold 8,770 shares at a weighted average price of $621.29 (ranging from $620.00 to $623.90), realizing $5,448,713.30.
• Aggregate Volume & Value: 24,741 shares disposed at an average effective price of ~$621.00 per share, yielding aggregate proceeds of $15,364,148.94.

Trading Mechanism & Ownership Impact

• Order Structure: According to Footnote 1, transactions were executed pursuant to a limit order placed during an open trading window rather than an established Rule 10b5-1 pre-scheduled trading plan (box aff10b5One marked 0).
• Remaining Holdings: Following these transactions, Dr. Troendle directly holds 515,153 shares. In addition, he indirectly controls 4,733,019 shares through Medpace Investors, LLC, where he serves as the sole manager and controlling unit holder.
• Position Impact: The sale represents approximately 4.58% of his directly held shares and less than 0.5% of his total combined direct and indirect beneficial ownership (5,248,172 shares remaining), demonstrating that he retains a dominant equity stake in the company.

Trading Significance

Given the non-10b5-1 discretionary nature and eight-figure dollar value ($15.36M) executed by the founder and CEO, this transaction carries High visibility, although it represents only a modest reduction in Dr. Troendle's overall multi-million share beneficial position.